Table 1.
Patient demographics, baseline laboratory studies, chemotherapy dosing, and treatment-related complications
| All patients (n = 34) | |
| Gender | |
| Male | 12 (35.3%) |
| Female | 22 (64.7%) |
| Age (years) | 56.5 (30–85) |
| KPS | 80 (60–90) |
| Diagnosis | |
| ICC | 26 (76.5%) |
| HCC | 8 (23.5%) |
| Previous treatmenta | 7 (20.6%) |
| Ablationb | 5 |
| Systemic chemotherapy | 3 |
| Resection | 2 |
| % Liver involvement | 45% (30–80%) |
| Multifocal hepatic disease | 21 (61.8%) |
| Largest tumor diameter (cm) | 9.7 (2.7–18.1) |
| Chronic hepatitis (serology) | 4 (11.8%) |
| Cirrhosis/fibrosis (histology) | 5 (14.7%) |
| Pretreatment laboratory studies | |
| Alkaline phosphatase (μg/l) | 154.5 (76–1147) |
| Albumin (g/dl) | 3.3 (1.8–4.2) |
| Total bilirubin (mg/dl) | 0.7 (0.3–2.4) |
| LDH (μg/l) | 167 (121–318) |
| AST | 42.5 (21–249) |
| ALT | 44 (13–343) |
| INR | 1.06 (0.85–1.53) |
| Platelets (103/ml) | 244 (102–806) |
| Hemoglobin (g/dl) | 11.0 (8.1–14.0) |
| Pretreatment serum tumor marker levels | |
| AFP (ng/ml) | 4.8 (1.1–80003) |
| CA19-9 (μg/l) | 44 (0–19700) |
| CEA (ng/ml) | 2.2 (0.5–52.7) |
a
Three patients were treated with more than one modality.
b
Hepatic artery embolization/chemoembolization or ethanol injection.
ICC, intrahepatic cholangiocarcinoma; HCC, hepatocellular carcinoma; LDH, lactate dehydrogenase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; AFP, α-fetoprotein; CEA, carcinoembryonic antigen.